TRISENOX Side Effects

7020775-5 | Angina Unstable, Electrocardiogram Change, Thrombocytopenia
on Sep 22, 2010 Male patient from GERMANY , 71 years of age, weighting 176.4 lb, was diagnosed with acute myeloid leukaemia and was treated with Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: angina unstable, electrocardiogram change, thrombocytopenia. Trisenox dosage: . During the same period patient was treated with ATRA (View Atra Review and Atra Label ). Patient was hospitalized.

6970636-2 | Aphasia, Convulsion, Disseminated Intravascular Coagulation, Eczema, Haemorrhage Intracranial, Rash Maculo-papular, Skin Exfoliation, Tremor, Vision Blurred
Patient was taking Trisenox (View Usage). Patient had the following side effects: aphasia (What is aphasia?), convulsion, disseminated intravascular coagulation, eczema (What is eczema?), haemorrhage intracranial, rash maculo-papular, skin exfoliation, tremor, vision blurred on Sep 03, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 158.7 lb, was diagnosed with acute promyelocytic leukaemia, prophylaxis and. Trisenox dosage: . During the same period patient was treated with KEPPRA (View Keppra Review and Keppra Label ), VALACYCLOVIR HYDROCHLORIDE (View Valacyclovir Hydrochloride Review and Valacyclovir Hydrochloride Label ), ALUMINUM HYDROXIDE (View Aluminum Hydroxide Review and Aluminum Hydroxide Label ), ONDANSETRON HCL (View Ondansetron Hcl Review and Ondansetron Hcl Label ), ATARAX (View Atarax Review and Atarax Label ), MAALOX (View Maalox Review and Maalox Label ), PRILOSEC (View Prilosec Review and Prilosec Label ). Patient was hospitalized and became disabled.

6932650-2 | Hydrocephalus, Leukocytoclastic Vasculitis
Adverse event was reported on Aug 11, 2010 by a Female patient taking Trisenox (View Usage) (Dosage: ) was diagnosed with acute promyelocytic leukaemia, prophylaxis, viral infection (What is viral infection?) and. Location: ITALY , weighting 138.9 lb, After Trisenox was administered, patient had the following side effects: hydrocephalus (What is hydrocephalus?), leukocytoclastic vasculitis. During the same period patient was treated with ATRA (View Atra Review and Atra Label ), COTRIM (View Cotrim Review and Cotrim Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), GENTAMICIN (View Gentamicin Review and Gentamicin Label ). Patient was hospitalized.

6930884-4 | Meningoencephalitis Herpetic, Pancytopenia
on Aug 12, 2010 Female patient from UNITED STATES , weighting 169.8 lb, was diagnosed with glioblastoma multiforme and was treated with Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: meningoencephalitis herpetic, pancytopenia. Trisenox dosage: . During the same period patient was treated with TEMOZOLOMIDE (View Temozolomide Review and Temozolomide Label ), DECADRON (View Decadron Review and Decadron Label ), CRESTOR (View Crestor Review and Crestor Label ), K DUR (View K-dur Review and K-dur Label ), NEXIUM (View Nexium Review and Nexium Label ), XALATAN (View Xalatan Review and Xalatan Label ), NIACIN (View Niacin Review and Niacin Label ), ZYPREXA (View Zyprexa Review and Zyprexa Label ). Patient was hospitalized.


6826164-8 | Chest Pain, Dyspnoea, Pericardial Effusion
on Jul 08, 2010 Male patient from UNITED STATES , weighting 163.1 lb, was treated with Trisenox (View Usage). Patient had the following side effects: chest pain (What is chest pain?), dyspnoea, pericardial effusion. Trisenox dosage: 111.1 Mg. Patient was hospitalized.

6784706-5 | Mucormycosis
Patient was taking Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: mucormycosis on Jun 15, 2010 from GERMANY Additional patient health information: Male patient , 75 years of age, was diagnosed with myelodysplastic syndrome and. Trisenox dosage: .

6783539-3 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Gamma-glutamyltransferase Increased
Adverse event was reported on Jun 16, 2010 by a Female patient taking Trisenox (View Usage) (Dosage: ) . Location: GERMANY , weighting 176.4 lb, Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased. During the same period patient was treated with ALL TRANS RETINOIC ACID (View All-trans Retinoic Acid Review and All-trans Retinoic Acid Label ).

6762988-3 | Ejection Fraction Decreased, Oedema, Weight Increased
on Jun 02, 2010 Male patient from UNITED STATES , weighting 229.3 lb, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient had the following side effects: ejection fraction decreased, oedema, weight increased. Trisenox dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), ATRA (View Atra Review and Atra Label ), COMPAZINE (View Compazine Review and Compazine Label ).

6750126-2 | Lung Infiltration
on May 26, 2010 Male patient from UNITED STATES , weighting 178.6 lb, was diagnosed with myelofibrosis and was treated with Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: lung infiltration. Trisenox dosage: . During the same period patient was treated with MAG PLUS PROTEIN (View Mag Plus Protein Review and Mag Plus Protein Label ), ENALAPRIL (View Enalapril Review and Enalapril Label ), VITAMIN C (View Vitamin C Review and Vitamin C Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), SPIRIVA (View Spiriva Review and Spiriva Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), FINASTERIDE (View Finasteride Review and Finasteride Label ). Patient was hospitalized.

6739178-3 | Weight Increased
Patient was taking Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: weight increased on May 19, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 304.2 lb, was diagnosed with endometrial cancer, hypertension, deep vein thrombosis (What is deep vein thrombosis?), pulmonary embolism (What is pulmonary embolism?) and. Trisenox dosage: . During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), DIOVAN (View Diovan Review and Diovan Label ), LOVENOX (View Lovenox Review and Lovenox Label ). Patient was hospitalized.

6734694-2 | Dyspnoea Exertional, Metal Poisoning, Treatment Noncompliance, Weight Increased
Adverse event was reported on May 19, 2010 by a Female patient taking Trisenox (View Usage) (Dosage: 0.25mg/kg/day Iv) was diagnosed with endometrial cancer and. Location: UNITED STATES , weighting 303.6 lb, Patient had the following side effects: dyspnoea exertional, metal poisoning, treatment noncompliance, weight increased. During the same period patient was treated with LASIX (View Lasix Review and Lasix Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), DIOVAN (View Diovan Review and Diovan Label ), LOVENOX (View Lovenox Review and Lovenox Label ), MAGNESIUM SULFATE (View Magnesium Sulfate Review and Magnesium Sulfate Label ). Patient was hospitalized.

6707820-9 | Fall, Hepatic Failure, Renal Failure, Respiratory Failure
on Apr 26, 2010 Female patient from UNITED STATES , 39 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: fall (What is fall?), hepatic failure, renal failure, respiratory failure. Trisenox dosage: . During the same period patient was treated with ATRA (View Atra Review and Atra Label ).

6604992-1 | Bone Marrow Necrosis
on Feb 11, 2010 Male patient from FRANCE , 53 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow necrosis. Trisenox dosage: Intravenous. During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ATRACURIUM BESYLATE (View Atracurium Besylate Review and Atracurium Besylate Label ). Patient was hospitalized.

6583028-5 | Ventricular Tachycardia
Patient was taking Trisenox (View Usage). Patient had the following side effects: ventricular tachycardia on Dec 14, 2009 from JAPAN Additional patient health information: Female patient , 68 years of age, . Trisenox dosage: Intravenous Drip.

6580151-6 | H1n1 Influenza, Hepatotoxicity, Pneumonia Influenzal
Adverse event was reported on Jan 25, 2010 by a Female patient taking Trisenox (View Usage) (Dosage: Intravenous Drip; (at 75% Of Dose), Intravenous; (100% Of Weight Adjusted Dose.), Intravenous) was diagnosed with acute promyelocytic leukaemia and. Location: SPAIN , 15 years of age, After Trisenox was administered, patient had the following side effects: h1n1 influenza, hepatotoxicity, pneumonia influenzal. During the same period patient was treated with TRETINOIN (View Tretinoin Review and Tretinoin Label ).

6567105-0 | Ejection Fraction Decreased, Oedema, Weight Increased
on Jan 19, 2010 Male patient from UNITED STATES , 24 years of age, weighting 230.0 lb, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: ejection fraction decreased, oedema, weight increased. Trisenox dosage: 8.6786 Mg (12.15 Mg, 5 In 1 Wk), Intravenous Drip; 10.1071 Mg (14.15 Mg, 5 In 1 Wk), Intravenous. During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), TRETINOIN (View Tretinoin Review and Tretinoin Label ), COMPAZINE (View Compazine Review and Compazine Label ).

6537958-0 | Acute Promyelocytic Leukaemia Differentiation Syndrome, Clostridium Colitis, Febrile Neutropenia, Headache, Herpes Zoster, Leukaemia Recurrent, Monocyte Count Increased, Pseudomembranous Colitis, Rash Pustular
on Dec 02, 2009 Male patient from JAPAN , 59 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient had the following side effects: acute promyelocytic leukaemia differentiation syndrome, clostridium colitis, febrile neutropenia, headache (What is headache?), herpes zoster, leukaemia recurrent, monocyte count increased, pseudomembranous colitis, rash pustular. Trisenox dosage: (9.4 Mg), Intravenous Drip. During the same period patient was treated with VESANOID (140 Mg (140 Mg, 1 In 1 D), Oral) (View Vesanoid Review and Vesanoid Label ).

6535868-6 | Adrenal Insufficiency, Back Pain, Bacterial Infection, Cardiac Arrest, Cellulitis, Confusional State, Delirium, Ecchymosis
Patient was taking Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: adrenal insufficiency, back pain (What is back pain?), bacterial infection (What is bacterial infection?), cardiac arrest (What is cardiac arrest?), cellulitis (What is cellulitis?), confusional state, delirium, ecchymosis on Dec 28, 2009 from UNITED STATES Additional patient health information: Male patient , 61 years of age, weighting 185.2 lb, was diagnosed with acute myeloid leukaemia and. Trisenox dosage: See Image. During the same period patient was treated with DECITABINE (DECITABINE) (920 Mg/m2, Days 1-5 Qw), Intravenous) (View Decitabine (decitabine) Review and Decitabine (decitabine) Label ), ASCORBIC ACID (See Image) (View Ascorbic Acid Review and Ascorbic Acid Label ), COMPAZINE (View Compazine Review and Compazine Label ). Patient was hospitalized.

6522700-X | Hepatotoxicity
Adverse event was reported on Dec 11, 2009 by a Female patient taking Trisenox (View Usage) (Dosage: Intravenous Drip) was diagnosed with acute promyelocytic leukaemia and. Location: SPAIN , 15 years of age, Patient experienced the following unwanted or unexpected effects: hepatotoxicity.

6504317-6 | Arteriospasm Coronary, Arthralgia, Atelectasis, Back Pain, Blood Alkaline Phosphatase Increased, Blood Pressure Decreased, Bundle Branch Block Right, Coagulopathy, Dizziness
on Dec 07, 2009 Male patient from UNITED KINGDOM , 47 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient had the following side effects: arteriospasm coronary, arthralgia, atelectasis, back pain (What is back pain?), blood alkaline phosphatase increased, blood pressure decreased, bundle branch block right, coagulopathy, dizziness (What is dizziness?). Trisenox dosage: (17 Mg), Intravenous Drip. During the same period patient was treated with TRETINOIN ((50 Mg), Oral) (View Tretinoin Review and Tretinoin Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), CORSODYL (CHLORHEXIDINE GLUCONATE) (View Corsodyl (chlorhexidine Gluconate) Review and Corsodyl (chlorhexidine Gluconate) Label ), DIFFLAM (BENZYDAMINE HYDROCHLORIDE) (View Difflam (benzydamine Hydrochloride) Review and Difflam (benzydamine Hydrochloride) Label ), NYSTATIN (View Nystatin Review and Nystatin Label ). Patient was hospitalized.

6499821-3 | Acute Myeloid Leukaemia, Back Pain, Cellulitis, Disease Progression, Hypotension, Malaise, Pancytopenia, Pseudomonas Infection
on Dec 02, 2009 Male patient from UNITED STATES , 61 years of age, weighting 185.2 lb, was diagnosed with acute myeloid leukaemia and was treated with Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: acute myeloid leukaemia, back pain (What is back pain?), cellulitis (What is cellulitis?), disease progression, hypotension, malaise, pancytopenia, pseudomonas infection. Trisenox dosage: (0.3 Mg/kg, Days 1-5 Qw), Intraveous Drip. During the same period patient was treated with DECITABINE (DECITABINE) ((20 Mg/m2,days 1-5 Qw), Intravenous) (View Decitabine (decitabine) Review and Decitabine (decitabine) Label ), COMPAZINE (View Compazine Review and Compazine Label ), DILAUDID (View Dilaudid Review and Dilaudid Label ), MS CONTIN (View Ms Contin Review and Ms Contin Label ), NEXIUM (View Nexium Review and Nexium Label ), FLOMAX (MORNIFLUMATE) (View Flomax (morniflumate) Review and Flomax (morniflumate) Label ). Patient was hospitalized.

6497487-X | Hydrocephalus, Leukocytoclastic Vasculitis
Patient was taking Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: hydrocephalus (What is hydrocephalus?), leukocytoclastic vasculitis on Dec 01, 2009 from ITALY Additional patient health information: Female patient , 61 years of age, weighting 138.9 lb, . Trisenox dosage: 10 Mg, Intravenous Drip. During the same period patient was treated with ATRACURIUM BESYLATE (View Atracurium Besylate Review and Atracurium Besylate Label ), COTRIM (View Cotrim Review and Cotrim Label ), CEFOTRIX (CEFADROXIL) (View Cefotrix (cefadroxil) Review and Cefotrix (cefadroxil) Label ), ACIC (ACICLOVIR) (View Acic (aciclovir) Review and Acic (aciclovir) Label ), GENTAMICIN (View Gentamicin Review and Gentamicin Label ). Patient was hospitalized.

6496366-1 | Disease Progression, Infection In An Immunocompromised Host, Nervous System Disorder, Nuclear Magnetic Resonance Imaging Brain Abnormal
Adverse event was reported on Dec 02, 2009 by a Female patient taking Trisenox (View Usage) (Dosage: Intravenous Drip) was diagnosed with acute promyelocytic leukaemia and. Location: IRELAND , 36 years of age, Patient had the following side effects: disease progression, infection in an immunocompromised host, nervous system disorder, nuclear magnetic resonance imaging brain abnormal.

6489672-8 | Cardiac Arrest
on Dec 01, 2009 Female patient from UNITED KINGDOM , 60 years of age, was diagnosed with acute myeloid leukaemia, myelodysplastic syndrome and was treated with Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: cardiac arrest (What is cardiac arrest?). Trisenox dosage: Intravenous Drip. During the same period patient was treated with ATRA (TRETINOIN) (View Atra (tretinoin) Review and Atra (tretinoin) Label ), MYLOTARG (View Mylotarg Review and Mylotarg Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), GLICLAZIDE (GLICLAZIDE) (View Gliclazide (gliclazide) Review and Gliclazide (gliclazide) Label ).

6485774-0 | Acute Myeloid Leukaemia, Arthralgia, Dyspnoea, Malignant Neoplasm Progression, Muscular Weakness, Myalgia, Pneumonia, Respiratory Failure
on Dec 02, 2009 Male patient from UNITED STATES , 24 years of age, weighting 138.9 lb, was diagnosed with acute myeloid leukaemia and was treated with Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, arthralgia, dyspnoea, malignant neoplasm progression, muscular weakness, myalgia, pneumonia (What is pneumonia?), respiratory failure. Trisenox dosage: (day 1 Thru 5 Qw), Intravenous Drip. During the same period patient was treated with DECITABINE (DECITABINE) (20 MILLIGRAM(S) / KILOGRAM(S) /SQ. METER) ((day 1-5), Intravenous) (View Decitabine (decitabine) (20 Milligram(s) / Kilogram(s) /sq. Meter) Review and Decitabine (decitabine) (20 Milligram(s) / Kilogram(s) /sq. Meter) Label ), ASCORBIC ACID ((1000 Mg, Day 1-5), Intravenous) (View Ascorbic Acid Review and Ascorbic Acid Label ). Patient was hospitalized.

6480809-3 | Abdominal Pain, Acute Respiratory Failure, Atrial Fibrillation, Bronchopulmonary Aspergillosis, Fatigue, Fungal Infection, Leukaemia Recurrent, Renal Failure Acute, Septic Shock
Patient was taking Trisenox (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), acute respiratory failure, atrial fibrillation (What is atrial fibrillation?), bronchopulmonary aspergillosis, fatigue, fungal infection (What is fungal infection?), leukaemia recurrent, renal failure acute, septic shock on Nov 23, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 253.5 lb, was diagnosed with acute myeloid leukaemia and. Trisenox dosage: (dasy 1-5 Qw), Intravenous Drip. During the same period patient was treated with DECITABINE (DECITABINE) (20 MICROGRAM(S) /SW.METER) ((days 1-5 Qw), Intravenous) (View Decitabine (decitabine) (20 Microgram(s) /sw.meter) Review and Decitabine (decitabine) (20 Microgram(s) /sw.meter) Label ), ASCORBIC ACID ((1000 Mg, Days 1-5 Qw), Intravenous) (View Ascorbic Acid Review and Ascorbic Acid Label ). Patient was hospitalized.

6472185-7 | Cardiac Arrest
Adverse event was reported on Nov 25, 2009 by a Female patient taking Trisenox (View Usage) (Dosage: Intravenous Drip) was diagnosed with acute myeloid leukaemia, myelodysplastic syndrome and. Location: UNITED KINGDOM , 60 years of age, After Trisenox was administered, patient had the following side effects: cardiac arrest (What is cardiac arrest?). During the same period patient was treated with ATRA (TRETINOIN) (View Atra (tretinoin) Review and Atra (tretinoin) Label ), MYLOTARG (View Mylotarg Review and Mylotarg Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), GLICLAZIDE (GLICLAZIDE) (View Gliclazide (gliclazide) Review and Gliclazide (gliclazide) Label ).

6466371-X | Bacteraemia, Cellulitis, Device Related Infection, Hypotension, Neutropenic Sepsis
on Nov 18, 2009 Male patient from UNITED STATES , 61 years of age, weighting 189.6 lb, was diagnosed with acute myeloid leukaemia and was treated with Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: bacteraemia, cellulitis (What is cellulitis?), device related infection, hypotension, neutropenic sepsis. Trisenox dosage: 0.3 Mg/kg, Days 1-5 Qw, Intravenous Drip. During the same period patient was treated with DECITABINE (DECITABINE) (20 Mg/m2, Days 1-5) (View Decitabine (decitabine) Review and Decitabine (decitabine) Label ), ASCORBIC ACID (1000 Mg, Days 1-5) (View Ascorbic Acid Review and Ascorbic Acid Label ). Patient was hospitalized.

6465657-2 | Confusional State, Dry Mouth, Oropharyngeal Discomfort
on Nov 16, 2009 Male patient from FRANCE , 60 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient had the following side effects: confusional state, dry mouth, oropharyngeal discomfort. Trisenox dosage: (15 Mg), Intravenous Drip. Patient was hospitalized.

6465640-7 | Ventricular Tachycardia
Patient was taking Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: ventricular tachycardia on Sep 15, 2009 from JAPAN Additional patient health information: Female patient , 68 years of age, . Trisenox dosage: Intravenous Drip.

6463111-5 | Pleural Effusion, Pneumonia
Adverse event was reported on Nov 12, 2009 by a Male patient taking Trisenox (View Usage) (Dosage: (0.3 Mg/kg, Cycle 2 Days 1-5 Qw), Intravenous Drip) was diagnosed with acute myeloid leukaemia and. Location: UNITED STATES , 61 years of age, weighting 200.6 lb, Patient experienced the following unwanted or unexpected effects: pleural effusion, pneumonia (What is pneumonia?). During the same period patient was treated with DECITABINE (DECITABINE) ((20 Mg/m2, Cycle 2 Days 1-5), Intravenous) (View Decitabine (decitabine) Review and Decitabine (decitabine) Label ), ASCORBIC ACID ((100 Mg, Cycle 2 Days 1-5 Qw), Intravenous) (View Ascorbic Acid Review and Ascorbic Acid Label ). Patient was hospitalized.

6463110-3 | Brain Natriuretic Peptide Increased, Device Related Sepsis, Dyspnoea, Headache, Hyperdynamic Left Ventricle, Joint Swelling, Medical Device Complication, Middle Insomnia, Venous Insufficiency
on Nov 11, 2009 Male patient from UNITED STATES , 76 years of age, was diagnosed with acute myeloid leukaemia and was treated with Trisenox (View Usage). Patient had the following side effects: brain natriuretic peptide increased, device related sepsis, dyspnoea, headache (What is headache?), hyperdynamic left ventricle, joint swelling, medical device complication, middle insomnia, venous insufficiency. Trisenox dosage: (0.2 Mg/kg, D1-5), Intravenous. During the same period patient was treated with ASCORBIC ACID ((1000 Mg, D1-5), Intravenous) (View Ascorbic Acid Review and Ascorbic Acid Label ), DECITABINE (DECITABINE) ((20 Mg/m2, D1-5), Intravenous) (View Decitabine (decitabine) Review and Decitabine (decitabine) Label ). Patient was hospitalized.

6463109-7 | Acute Myeloid Leukaemia, Arthralgia, Malignant Neoplasm Progression, Muscular Weakness, Myalgia, Peripheral Motor Neuropathy
on Nov 12, 2009 Male patient from UNITED STATES , 24 years of age, weighting 138.9 lb, was diagnosed with acute myeloid leukaemia and was treated with Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: acute myeloid leukaemia, arthralgia, malignant neoplasm progression, muscular weakness, myalgia, peripheral motor neuropathy. Trisenox dosage: See Image. During the same period patient was treated with DECITABINE (DECITABINE) (20 MILLIGRAM(S)/SQ.METER) ((day 1-5), Intravenous) (View Decitabine (decitabine) (20 Milligram(s)/sq.meter) Review and Decitabine (decitabine) (20 Milligram(s)/sq.meter) Label ), ASCORBIC ACID (See Image) (View Ascorbic Acid Review and Ascorbic Acid Label ). Patient was hospitalized.

6461338-X | Diarrhoea, Nephrotic Syndrome, Pancytopenia, Splenic Infarction
Patient was taking Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, nephrotic syndrome, pancytopenia, splenic infarction on Nov 12, 2009 from UNITED STATES Additional patient health information: Male patient , 54 years of age, weighting 253.5 lb, was diagnosed with acute myeloid leukaemia and. Trisenox dosage: 0.3 Mg/kg, D1-5, Intravenous. During the same period patient was treated with DECITABINE (DECITABINE) (20 Mg/m2, D1-5, Intravenous) (View Decitabine (decitabine) Review and Decitabine (decitabine) Label ), ASCORBIC ACID (1000 Mg, D1-5, Intravenous) (View Ascorbic Acid Review and Ascorbic Acid Label ). Patient was hospitalized.

6446557-0 | Cough, Dyspnoea, Electrocardiogram Qt Prolonged, Hypotension, Pneumonia, Respiratory Alkalosis
Adverse event was reported on Nov 11, 2009 by a Female patient taking Trisenox (View Usage) (Dosage: (0.3 Mg/m2, Day 1-5; Weekly), Intravenous) was diagnosed with myeloid leukaemia and. Location: UNITED STATES , 69 years of age, weighting 172.0 lb, Patient had the following side effects: cough, dyspnoea, electrocardiogram qt prolonged, hypotension, pneumonia (What is pneumonia?), respiratory alkalosis. During the same period patient was treated with DECITABINE (DECITABINE) ((20 Mg/m2, Day 1-5; Weekly), Intravenous) (View Decitabine (decitabine) Review and Decitabine (decitabine) Label ), ASCORBIC ACID ((1000 Mg, Day 1-5;) (View Ascorbic Acid Review and Ascorbic Acid Label ). Patient was hospitalized.

6417026-9 | Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukaemia Differentiation Syndrome, Blood Lactate Dehydrogenase Increased, Febrile Neutropenia, Headache, Herpes Zoster, Leukaemia Recurrent, Monocyte Count Increased, Pseudomembranous Colitis
on Oct 09, 2009 Male patient from JAPAN , 59 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: acute promyelocytic leukaemia, acute promyelocytic leukaemia differentiation syndrome, blood lactate dehydrogenase increased, febrile neutropenia, headache (What is headache?), herpes zoster, leukaemia recurrent, monocyte count increased, pseudomembranous colitis. Trisenox dosage: (9.4 Mg), Intravenous Drip. During the same period patient was treated with VESANOID (140 Mg (140 Mg, 1 In 1 D), Oral) (View Vesanoid Review and Vesanoid Label ).

6406400-2 | Dysstasia, Feeling Abnormal, Gait Disturbance, Hypoaesthesia, Monoplegia, Muscular Weakness, Nervous System Disorder, Paralysis, Pyramidal Tract Syndrome
on Oct 07, 2009 Male patient from JAPAN , 35 years of age, was diagnosed with acute leukaemia, leukaemic infiltration extramedullary and was treated with Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: dysstasia, feeling abnormal, gait disturbance, hypoaesthesia, monoplegia, muscular weakness, nervous system disorder, paralysis (What is paralysis?), pyramidal tract syndrome. Trisenox dosage: (10 Mg, Intravenous. During the same period patient was treated with CYTARABINE (40 Mg Total Daily Dose (40 Mg Total Daily Dose (40 Mg), Intrathecal) (View Cytarabine Review and Cytarabine Label ), METHOTREXATE (15 Mg Total Daily Dose (15 Mg), Intrathecal) (View Methotrexate Review and Methotrexate Label ), PREDNISOLONE SODIUM SUCINATE (PREDNISOLONE SODIUM SUCCINATE) (20 Mg Total Daily Dose (20 Mg), Intathecal) (View Prednisolone Sodium Sucinate (prednisolone Sodium Succinate) Review and Prednisolone Sodium Sucinate (prednisolone Sodium Succinate) Label ).

6381213-9 | Gastroenteritis Viral, Pancytopenia
Patient was taking Trisenox (View Usage). Patient had the following side effects: gastroenteritis viral, pancytopenia on May 25, 2009 from FRANCE Additional patient health information: Female patient , 33 years of age, was diagnosed with acute promyelocytic leukaemia and. Trisenox dosage: Intravenous Drip.

6381212-7 | Cardiac Failure, Cardiomyopathy, Lung Disorder
Adverse event was reported on May 25, 2009 by a Female patient taking Trisenox (View Usage) (Dosage: Intravenous) was diagnosed with acute promyelocytic leukaemia and. Location: FRANCE , 39 years of age, After Trisenox was administered, patient had the following side effects: cardiac failure, cardiomyopathy (What is cardiomyopathy?), lung disorder.

6381211-5 | Cytolytic Hepatitis
on May 25, 2009 Female patient from FRANCE , 79 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: cytolytic hepatitis. Trisenox dosage: Intravenous Drip. During the same period patient was treated with PURINETHOL (View Purinethol Review and Purinethol Label ), METHOTREXATE (METHOTREXATE) (View Methotrexate (methotrexate) Review and Methotrexate (methotrexate) Label ).

6381210-3 | Acute Pulmonary Oedema, Dementia Alzheimer's Type, Depression, Disseminated Intravascular Coagulation, Mental Disorder, Mucosal Inflammation, Retinoic Acid Syndrome, Subdural Haematoma
on May 25, 2009 Female patient from FRANCE , 68 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient had the following side effects: acute pulmonary oedema, dementia alzheimer's type, depression (What is depression?), disseminated intravascular coagulation, mental disorder, mucosal inflammation, retinoic acid syndrome, subdural haematoma. Trisenox dosage: Intravenous Drip. Patient was hospitalized.

6381209-7 | Bone Tuberculosis, Febrile Bone Marrow Aplasia, Respiratory Distress
Patient was taking Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: bone tuberculosis, febrile bone marrow aplasia, respiratory distress on May 25, 2009 from FRANCE Additional patient health information: Male patient , 43 years of age, was diagnosed with acute promyelocytic leukaemia and. Trisenox dosage: Intravenous.

6381204-8 | Heart Rate Abnormal, Hypokalaemia, Streptococcal Sepsis
Adverse event was reported on May 25, 2009 by a Male patient taking Trisenox (View Usage) (Dosage: Intravenous) was diagnosed with acute promyelocytic leukaemia and. Location: FRANCE , 77 years of age, Patient experienced the following unwanted or unexpected effects: heart rate abnormal, hypokalaemia, streptococcal sepsis.

6372116-4 | Cardiac Arrest, Cardiac Failure, Hepatic Pain, Lung Disorder, Orthopnoea, Pyrexia, Urine Output Decreased
on Sep 14, 2009 Female patient from FRANCE , child 2 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?), cardiac failure, hepatic pain, lung disorder, orthopnoea, pyrexia, urine output decreased. Trisenox dosage: Intravenous Drip. During the same period patient was treated with ANTHRACYCLINE (ANTHRACYCLINES) (Intravenous) (View Anthracycline (anthracyclines) Review and Anthracycline (anthracyclines) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), DAUNORUBICINE (DAUNORUBICIN) (View Daunorubicine (daunorubicin) Review and Daunorubicine (daunorubicin) Label ).

6347574-1 | Dyspnoea, Ear Pain, Electrocardiogram St-t Change, Hepatic Function Abnormal, Hypotension, Hypoxia, Musculoskeletal Pain, Oropharyngeal Pain, Renal Failure Acute
on Sep 09, 2009 Female patient from UNITED STATES , weighting 168.2 lb, was treated with Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: dyspnoea, ear pain, electrocardiogram st-t change, hepatic function abnormal, hypotension, hypoxia, musculoskeletal pain, oropharyngeal pain, renal failure acute. Trisenox dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), TRETINOIN (View Tretinoin Review and Tretinoin Label ). Patient was hospitalized.

6344839-4 | Acute Respiratory Distress Syndrome, Cardiac Failure Congestive, Haemoglobin Decreased, Mitral Valve Incompetence, Platelet Count Decreased, Pneumonia, Pulmonary Oedema, Tachycardia, Type 2 Diabetes Mellitus
Patient was taking Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: acute respiratory distress syndrome, cardiac failure congestive, haemoglobin decreased, mitral valve incompetence, platelet count decreased, pneumonia (What is pneumonia?), pulmonary oedema, tachycardia, type 2 diabetes mellitus on Aug 21, 2009 from UNITED STATES Additional patient health information: Female patient , 76 years of age, weighting 161.6 lb, was diagnosed with acute myeloid leukaemia and. Trisenox dosage: 16.4 Mg (16.4 Mg, 1 In 1 D), Intravenous. During the same period patient was treated with CYTARABINE (33.8 Mg (16.9 Mg, 2 In 1 D), Subcutaneous) (View Cytarabine Review and Cytarabine Label ), ARTIFICIAL TEARS (HYPROMELLOSE) (View Artificial Tears (hypromellose) Review and Artificial Tears (hypromellose) Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), XALATAN (View Xalatan Review and Xalatan Label ), LIPITOR (View Lipitor Review and Lipitor Label ). Patient was hospitalized.

6338363-2 | Febrile Neutropenia, Pleural Effusion, Subdural Haematoma, Thrombocytopenia
Adverse event was reported on Aug 24, 2009 by a Male patient taking Trisenox (View Usage) (Dosage: 16.9 Mg (16.9 Mg, 1 In 1 D), Intravenous) was diagnosed with myelodysplastic syndrome and. Location: UNITED STATES , 66 years of age, weighting 149.9 lb, Patient had the following side effects: febrile neutropenia, pleural effusion, subdural haematoma, thrombocytopenia. During the same period patient was treated with DECITABINE (DECITABINE) (36 Mg (36 Mg, 1 In 1 D), Intravenous) (View Decitabine (decitabine) Review and Decitabine (decitabine) Label ), ASCORIC ACID (ASCORBIC ACID) (View Ascoric Acid (ascorbic Acid) Review and Ascoric Acid (ascorbic Acid) Label ), EXJADE (View Exjade Review and Exjade Label ), MIRALAX (View Miralax Review and Miralax Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ). Patient was hospitalized.

6335470-5 | Acute Pulmonary Oedema
on May 25, 2009 Female patient from FRANCE , 75 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). After Trisenox was administered, patient had the following side effects: acute pulmonary oedema. Trisenox dosage: Intravenous Drip.

6326584-4 | Cytolytic Hepatitis
on May 25, 2009 Female patient from FRANCE , 31 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox (View Usage). Patient experienced the following unwanted or unexpected effects: cytolytic hepatitis. Trisenox dosage: Intravenous Drip.

6326577-7 | Febrile Bone Marrow Aplasia
Patient was taking Trisenox (View Usage). Patient had the following side effects: febrile bone marrow aplasia on May 25, 2009 from FRANCE Additional patient health information: Male patient , 19 years of age, was diagnosed with acute promyelocytic leukaemia and. Trisenox dosage: Intravenous Drip.